Pursuant to Regulation 30 read with Schedule III to the SEBI Listing Regulations, Piramal Pharma has informed that the Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held on Friday, 26th July, 2024 approved grant of 4,830,836 stock options under the Plan 2022. The disclosure as required under Regulation 30 of SEBI Listing Regulations is enclosed as Annexure-1.
The above information is a part of company’s filings submitted to BSE.